These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 35154567)

  • 1. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer.
    Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z
    Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib enhanced CD8
    Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
    Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.
    Yang Y; Li L; Jiang Z; Wang B; Pan Z
    Cancer Immunol Immunother; 2020 Dec; 69(12):2523-2532. PubMed ID: 32577817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of radiotherapy and Anlotinib enhances benefit from immunotherapy to liver metastasis and abscopal tumor from lung cancer.
    Jiang Y; Qiao S; Li L; Zhu X
    Int Immunopharmacol; 2024 Feb; 128():111441. PubMed ID: 38171056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
    Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
    Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
    Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
    Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
    Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
    [No Abstract]   [Full Text] [Related]  

  • 11. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
    Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
    Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer.
    Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Yang X; Sun S; Bao Y; Liu Y; Hui Z
    Thorac Cancer; 2022 Dec; 13(23):3331-3340. PubMed ID: 36281217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8
    Song F; Hu B; Liang XL; Cheng JW; Wang CG; Wang PX; Wang TL; Tang PJ; Sun HX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Clin Transl Med; 2024 Aug; 14(8):e1738. PubMed ID: 39095323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8
    Wang H; Lin X; Luo Y; Sun S; Tian X; Sun Y; Zhang S; Chen J; Zhang J; Liu X; Liu H; Gong Y; Xie C
    Immunotherapy; 2019 Feb; 11(2):101-118. PubMed ID: 30511887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
    Du B; Wen X; Wang Y; Lin M; Lai J
    Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy.
    Wang H; Xia L; Yao CC; Dong H; Yang Y; Li C; Ji WX; Sun RM; Duan HQ; Mengzhou W; Xia WM; Wang SJ; Ji P; Li Z; Jiao L; Wang Y; Lu S
    Cancer Sci; 2022 Mar; 113(3):838-851. PubMed ID: 34927309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatial tertiary lymphoid structures imply response to anti-PD-1 plus anlotinib in advanced non-small cell lung cancer.
    Ma J; Deng Y; Zhang M; Zhang Q
    Immunology; 2024 Nov; 173(3):536-551. PubMed ID: 39078223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
    Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.